<DOC>
	<DOCNO>NCT02577523</DOCNO>
	<brief_summary>This multicenter , parallel-group , rater-blinded , randomized clinical study subject advance PD investigate efficacy , PK , safety tolerability continuous SC infusion 2 dosing regimen ND0612H , solution LD/CD deliver via pump system continuous SC infusion , compare standard oral LD/CD . After screen , subject undergo 1 day standard oral LD/CD inpatient dose follow 2 day inpatient treatment 1 2 randomly allocate ( 1:1 randomization ratio ) dose regimen ND0612H continuous SC infusion . Subjects continue maintenance dose assign ND0612H dose regimen next 25 day . A safety visit perform 4 week last SC administration study drug total 2.5 month participation subject enrol trial .</brief_summary>
	<brief_title>A Clinical Study Investigating Efficacy , Safety , Tolerability Pharmacokinetics ND0612H , Solution Levodopa/Carbidopa Administered Continuous Subcutaneous Infusion Subjects With Advanced Parkinson 's Disease</brief_title>
	<detailed_description>This phase IIa randomize , control , parallel-group study conduct 36 subject advance PD treat oral LD/CD stable dose predictable morning `` OFF '' period least 2.5 hrs daily `` OFF '' period . The study investigate efficacy , PK , safety tolerability continuous SC infusion 2 dosing regimen ND0612H . Regimen 1 employ continuous infusion 24 hr use low infusion rate night high rate daytime supplemental administration oral immediate release ( IR ) LD/CD morning . During inpatient period 3 day , site staff manage administration replacement infusion . On Day 4 subject discharge home study partner receive train administration infusion . A safety visit perform 4 week last SC administration study drug .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Male female PD subject race age 30 80 year sign Institutional Review Board/Ethics Committee ( IRB/EC ) approve informed consent form ( ICF ) . 2 . PD diagnosis consistent UK Brain Bank Criteria . 3 . Modified Hoehn &amp; Yahr scale `` ON '' state stage â‰¤3 . 4 . Taking least 4 doses/day LD ( least 3 doses/day Rytary ) taking , attempted take , least 2 class antiPD medication therapeutic dose least 30 consecutive day . 5 . Subjects must stable antiPD medication least 30 day Day 1 . 6 . Subjects may prior exposure SC apomorphine injections/infusion must stop administration least 4 week screen visit . Treatment apomorphine prohibit entire ND0612H treatment period . 7 . Must minimum 2.5 hr `` OFF '' time per day predictable early morning `` OFF '' period estimate subject . 8 . Must predictable well define early morning `` OFF '' period good response LD treatment early morning `` OFF '' judgement investigator . 9 . Mini Mental State Examination ( MMSE ) score &gt; 26 . 10 . No clinically significant medical , psychiatric laboratory abnormality investigator judge would unsafe noncompliant study . 11 . Female subject must surgically sterile , postmenopausal ( defined cessation menses least 1 year ) , willing practice highly effective method contraception . All female participant must nonlactating nonpregnant negative urine pregnancy test Screening Baseline . Female subject childbearing potential must practice highly effective method contraception ( e.g. , oral contraceptive , barrier method birth control [ e.g. , condom contraceptive foam , diaphragms contraceptive jelly ] , intrauterine device , partner vasectomy ) , 1 month enrollment , duration study , 3 month last dose study drug . 12 . Willingness ability comply study requirement 1 . Atypical secondary parkinsonism . 2 . Acute psychosis hallucination past 6 month . 3 . Any relevant medical , surgical , psychiatric condition , laboratory value , concomitant medication , opinion Investigator eligibility reviewer , make subject unsuitable study entry potentially unable complete aspect study . 4 . Prior neurosurgical procedure PD , duodopa treatment . 5 . Subjects history drug abuse alcoholism within past 12 month . 6 . Clinically significant ECG rhythm abnormality . 7 . Renal liver dysfunction may alter drug metabolism include : serum creatinine &gt; 1.3 mg/dL , serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 x upper limit normal ( ULN ) , total serum bilirubin &gt; 2.5 mg/dL . 8 . Subjects willing operate pump system .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>